Hologic (HOLX) AI Stock Analysis

• Market Cap: $16.45B
• Dividend Yield: N/A
• Average Volume (3M): 2.87M
• Price to Earnings (P/E): 30.7
• Beta (1Y): 0.08
• Revenue Growth: 1.28%
• EPS Growth: -17.73%
• Country: US
• Employees: 7,063
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.08
• Shares Outstanding: 222,419,280
• 10 Day Avg. Volume: 4,024,236
• 30 Day Avg. Volume: 2,870,341
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: 3.79
• Enterprise Value/Gross Profit: 7.31
• Enterprise Value/Ebitda: 15.19
• 1Y Price Target: $78.00
• Price Target Upside: 5.51% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 13

• Rating: 69 Neutral
• Price Target: $73.00 ▼(-1.26% Downside)

Hologic's overall stock score is driven by a positive earnings call that highlighted strong financial performance and strategic growth initiatives. However, declining profitability margins and a high P/E ratio weigh on the score. Technical indicators suggest a neutral market sentiment.

Positive Factors

Revenue Growth

Strong revenue growth reflects Hologic's effective market strategies and product demand, supporting long-term business expansion and stability.

Product Innovation

Innovative product launches like Genius AI Detection PRO enhance Hologic's competitive edge, driving future growth and market leadership in medical technology.

Cash Generation

Strong cash generation supports Hologic's ability to invest in R&D, pay down debt, and fund strategic initiatives, ensuring financial resilience.

Negative Factors

Profitability Decline

Declining profitability margins could pressure Hologic's ability to reinvest in growth and maintain competitive pricing, impacting long-term financial health.

Geopolitical Challenges

Geopolitical challenges in key markets like China may hinder revenue growth and disrupt supply chains, affecting Hologic's global operations.

Product Discontinuation

The strategic discontinuation of products can lead to short-term revenue loss, requiring effective replacement strategies to sustain growth.

Hologic Business Overview & Revenue Model

Company Description

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

How the Company Makes Money

Hologic generates revenue through multiple key streams, primarily from the sale of its medical devices and diagnostic products. The company earns substantial income from its breast health segment, which includes the sale of mammography systems, imaging systems, and related software. Additionally, the diagnostics segment contributes significantly to revenue through molecular testing products and assays for various diseases, including HPV and COVID-19. Hologic also benefits from recurring revenue through service contracts and consumables associated with its products. Strategic partnerships with healthcare providers, laboratories, and research institutions enhance its market reach and product offerings, further contributing to its earnings. Moreover, ongoing investments in R&D enable Hologic to innovate and expand its product portfolio, thus driving future revenue growth.

Hologic Financial Statement Overview

Summary

Hologic's financial performance shows resilience with strong revenue growth in the TTM period, but profitability margins have declined. The balance sheet remains stable with manageable leverage, though profitability metrics like ROE have weakened. Cash flow generation is solid, but declining free cash flow growth could be a concern if it continues. Overall, the company is navigating challenges with a stable financial position, but needs to focus on improving profitability and cash flow growth.

Income Statement

Hologic's income statement shows a mixed performance. The TTM data indicates a strong gross profit margin of 51.8%, but this is a decline from previous years. The net profit margin has also decreased to 13.8% from 19.6% in the last annual report. Revenue growth is positive at 30.8% TTM, indicating a recovery from previous declines. However, EBIT and EBITDA margins have decreased, suggesting pressure on operational efficiency.

Balance Sheet

The balance sheet reflects moderate leverage with a debt-to-equity ratio of 0.52, which is stable compared to the previous year. Return on equity has decreased to 11.5% TTM from 15.4% annually, indicating reduced profitability. The equity ratio remains stable, suggesting a balanced capital structure.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth, which is down by 3.11% TTM. The operating cash flow to net income ratio is healthy at 1.11, indicating good cash generation relative to net income. However, the free cash flow to net income ratio has slightly decreased, suggesting less cash available after capital expenditures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.04B	4.03B	4.03B	4.86B	5.63B	3.78B
Gross Profit	2.09B	2.23B	2.07B	3.00B	3.80B	2.23B
EBITDA	1.01B	1.30B	1.11B	2.11B	2.86B	1.50B
Net Income	557.10M	789.50M	456.00M	1.30B	1.87B	1.12B
Balance Sheet
Total Assets	8.81B	9.16B	9.14B	9.07B	8.92B	7.20B
Cash, Cash Equivalents and Short-Term Investments	1.88B	2.33B	2.72B	2.34B	1.17B	701.00M
Total Debt	2.52B	2.66B	2.90B	2.92B	3.14B	3.15B
Total Liabilities	3.96B	4.03B	4.12B	4.20B	4.70B	4.49B
Stockholders Equity	4.84B	5.13B	5.02B	4.88B	4.22B	2.71B
Cash Flow
Free Cash Flow	978.20M	1.15B	901.00M	2.00B	2.17B	740.20M
Operating Cash Flow	1.07B	1.29B	1.05B	2.13B	2.33B	896.60M
Investing Cash Flow	-946.30M	-781.00M	-152.10M	-206.30M	-1.33B	-141.60M
Financing Cash Flow	-835.60M	-1.11B	-483.20M	-756.00M	-529.80M	-659.90M

Hologic Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 73.93
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOLX, the sentiment is Positive. The current price of 73.93 is above the 20-day moving average (MA) of 68.36, above the 50-day MA of 67.45, and above the 200-day MA of 64.47, indicating a bullish trend. The MACD of 1.37 indicates Negative momentum. The RSI at 70.89 is Negative, neither overbought nor oversold. The STOCH value of 89.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HOLX.

Hologic Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ISRG	78 Outperform	$164.35B	64.57	16.84%	―	22.18%	21.37%
RMD	77 Outperform	$39.14B	28.21	25.86%	0.82%	9.84%	37.48%
WST	76 Outperform	$20.09B	41.85	17.72%	0.30%	2.88%	-5.50%
BDX	70 Outperform	$54.18B	33.99	6.26%	2.21%	7.86%	14.24%
HOLX	69 Neutral	$16.45B	30.67	11.38%	―	1.28%	-17.73%
BAX	54 Neutral	$11.68B	―	-3.30%	2.97%	-27.41%	67.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Hologic Corporate Events

Hologic Announces Acquisition Agreement with Blackstone and TPG

On October 21, 2025, Hologic, Inc. announced its entry into a definitive agreement to be acquired by Blackstone and TPG for up to $79 per share, valuing the company at approximately $18.3 billion. This acquisition, which includes a 46% premium on Hologic’s stock price prior to media reports, aims to strengthen Hologic’s leadership in women’s health and accelerate its growth. The transaction is expected to close in the first half of 2026, pending shareholder and regulatory approvals, and will result in Hologic’s delisting from Nasdaq. The deal includes significant minority investments from ADIA and GIC, and Hologic’s stockholders will receive $76 per share in cash plus a contingent value right of up to $3 per share based on future revenue milestones.

The most recent analyst rating on (HOLX) stock is a Hold with a $73.00 price target. To see the full list of analyst forecasts on Hologic stock, see the HOLX Stock Forecast page.

Hologic Extends CEO Stephen MacMillan’s Employment Agreement

On September 18, 2025, Hologic, Inc. announced an amendment to the employment agreement with its CEO, Stephen P. MacMillan, extending the term of the agreement. This extension reflects the company’s commitment to stable leadership, potentially impacting its strategic direction and reassuring stakeholders of continued executive oversight.

The most recent analyst rating on (HOLX) stock is a Hold with a $72.00 price target. To see the full list of analyst forecasts on Hologic stock, see the HOLX Stock Forecast page.

Hologic’s Earnings Call: Strong Q3 Performance and Optimism

Hologic’s Q3 FY2025 earnings call conveyed a strong sense of optimism, underscored by robust financial performance that exceeded expectations. The company reported impressive revenue and earnings per share (EPS) figures, driven by improvements in key segments such as Breast Health and successful integration of recent acquisitions. Despite facing challenges in markets like China and Africa, Hologic remains positive about its growth trajectory.

Hologic Reports Strong Q3 2025 Earnings, Exceeds Guidance

Hologic, Inc. is a medical technology company that specializes in women’s health, focusing on early detection and treatment through innovative solutions in diagnostics, breast health, and surgical products.